<DOC>
	<DOCNO>NCT00199095</DOCNO>
	<brief_summary>The aim study test feasibility efficacy dose reduce chemotherapy elderly patient newly diagnose acute lymphoblastic leukemia . The regimen consist induction phase I II follow cyclic consolidation cycle , reinduction maintenance therapy</brief_summary>
	<brief_title>Treatment Elderly Patients ( &gt; 65 Years ) With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>diagnosis acute lymphoblastic leukemia ( proB , common , preB , preT , Thy , mature T , BALL ) age &gt; 65 year write informed consent Karnofsky &gt; 50 % ( mainly cause leukemia ) laboratory diagnosis supportive pretreatment Creatinine &lt; 2 mg/dl Uric Acid &lt; 8 mg/dl Bilirubin &lt; 1.5 mg/dl ALA , ASA , AP &lt; 2.5 x ULN severe second disease ( e.g . renal failure , cardiomyopathy etc. , cause leukemia ) exclude treatment accord protocol severe psychiatric illness circumstance may compromise cooperation active second neoplasia clinical sign life threaten infection bleed , uncontrollable prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Elderly</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>